[Antimutagenic hypoxen activity in vivo]

Area of Science:

• Pharmacology
• Genetics
• Toxicology

Background:

• Genotoxicity is a significant concern in drug development and environmental health.
• Identifying effective genoprotective agents is crucial for mitigating DNA damage.
• Hypoxen is a poly(2,5-dihydroxyphenylene)-4-thiosulfonic acid sodium salt with potential therapeutic applications.

Purpose of the Study:

• To evaluate the antimutagenic and genoprotective effects of hypoxen.
• To compare the efficacy of hypoxen with a reference drug, sladex (aspartam).
• To investigate the impact of administration route and duration on hypoxen's protective activity.

Main Methods:

• Chromosome aberration assay in bone marrow cells of C57BL/6 mice.
• Administration of hypoxen (70 mg/kg, p.o. for five days, or 20 mg/kg, i.p.) concurrently with dioxidine (300 mg/kg, i.p.).
• Assessment of genotoxicity reduction over a 24-hour period.

Main Results:

• Intraperitoneal administration of hypoxen (20 mg/kg) simultaneously with dioxidine (300 mg/kg) reduced dioxidine-induced genotoxicity by 35%.
• A preliminary five-day oral administration of hypoxen (70 mg/kg) did not significantly decrease dioxidine-induced damage.
• The genoprotector activity of intraperitoneally injected hypoxen was more pronounced than that of sladex (aspartam).

Conclusions:

• Hypoxen exhibits significant genoprotective properties when administered intraperitoneally, particularly in combination with genotoxic agents like dioxidine.
• The route and duration of hypoxen administration influence its antimutagenic efficacy.
• Hypoxen presents a promising candidate for further investigation as a genoprotective agent.